[Therapy of castration-resistant prostate cancer]

about

[Therapy of castration-resistant prostate cancer]

Item

http://www.wikidata.org/entity/Q57133648

description

im August 2012 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 20 July 2012

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2012

@uk

name

[Therapy of castration-resistant prostate cancer]

@en

type

Item

label

[Therapy of castration-resistant prostate cancer]

@en

prefLabel

[Therapy of castration-resistant prostate cancer]

@en

P1476

[Therapy of castration-resistant prostate cancer]

@en

P2093

Andreas Reissigl

http://www.w3.org/2001/XMLSchema#string

Franz Stoiber

http://www.w3.org/2001/XMLSchema#string

Gero Kramer

http://www.w3.org/2001/XMLSchema#string

Maria De Santis

http://www.w3.org/2001/XMLSchema#string

Michael Rauchenwald

http://www.w3.org/2001/XMLSchema#string

Nikolaus Schmeller

http://www.w3.org/2001/XMLSchema#string

Renée Oismüller

http://www.w3.org/2001/XMLSchema#string

Steffen Krause

http://www.w3.org/2001/XMLSchema#string

Thomas Bauernhofer

http://www.w3.org/2001/XMLSchema#string

Thorsten Füreder

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

P2888

s00508-012-0206-1

P304

538-551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00508-012-0206-1

http://www.w3.org/2001/XMLSchema#string

P433

15-16

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Michael Krainer

P577

2012-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22815001

http://www.w3.org/2001/XMLSchema#string

P921

enzalutamide